Ariadna Boloix Amenós I am a postdoctoral researcher in the group of Childhood Cancer and Blood Disorders. Specifically, I am working on project based on the development and implementation of RNA-based therapies in clinical practice for the treatment of pediatric solid tumors. Instituciones de las que forman parte Investigador postdoctoral Cáncer y Enfermedades Hematológicas Infantiles Vall Hebron Institut de Recerca Email Ariadna Boloix Amenós Email Instituciones de las que forman parte Investigador postdoctoral Cáncer y Enfermedades Hematológicas Infantiles Vall Hebron Institut de Recerca I am a postdoctoral researcher in the group of Childhood Cancer and Blood Disorders. Specifically, I am working on project based on the development and implementation of RNA-based therapies in clinical practice for the treatment of pediatric solid tumors.
I graduated in Pharmacy at the University of Barcelona and next year I studied a master's degree in Biomedicine. In 2015 I started my PhD thesis in collaboration between the Childhood Cancer and Blood Disorders group of VHIR and the Nanomol group of ICMAB-CSIC. Since 2019 when I defended the thesis, I continued working in the preclinical development of a nanomedicine based on the use of lipidic nanoparticles conjugated to microRNAs for the treatment of neuroblastoma as well as other diseases that can be treated with RNA-based therapies. The results of this research are patented (WO2020229469) and are currently pending review for publication in the scientific journal Small. The nucleic acid administration platform developed in the group has generated the interest of different national or International research groups with which we collaborated or are collaborating. So far, my purpose has been to advance the levels of technological readiness (TRL) of microRNA-based nanomedicine, which has been carried out while participating in entrepreneurship and innovation programs (Seed Knowledge Grants Program 2018; Bcn Activa Pre-acceleration Program and Ignite Health Program organized by Biocat). Finally, to complement my training in relevant clinical preclinical studies and improve my knowledge of technology transfer, I began a postgraduate specialization in quality management (UOC).
Proyectos Development of prognostic and therapeutic tools targeting epigenetic regulators in metastatic neuroblastoma IP: Miguel Segura Ginard Colaboradores: María Rosario Pérez- Torres Lobato, Maria Jose Pérez García, Lorena Valero Arrese, Ariadna Boloix Amenós, Adria Molero Valenzuela, Khloud Abdo Soliman Elsharawy Entidad financiadora: Instituto de Salud Carlos III Financiación: 315000 Referencia: PI23/01144 Duración: 01/01/2024 - 31/12/2026 TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas IP: Begoña Benito Villabriga Colaboradores: Carmen Escudero Iriarte, Ventura i Expósito, Laia, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Bou Teen, Diana, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala Entidad financiadora: Instituto de Salud Carlos III Financiación: 2494527.53 Referencia: FORT23/00034 Duración: 01/01/2024 - 31/12/2027 Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders IP: Lucas Moreno Martín-Retortillo Colaboradores: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, María de los Ángeles Rodríguez Sánchez, Uría Oficialdegui, Maria Luz, Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Raquel Anta Peña, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Elisabet Megías Roda, Raquel Hladun Alvaro, Ariadna Boloix Amenós, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Júlia Sansa Girona, Gabriela Guillén Burrieza, Laura Alonso Garcia, Victoria Gutierrez Valle, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Elena Andretta, Claire Diot, Amira Idrizovic Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 60000 Referencia: 2021 SGR 00638 Duración: 01/01/2022 - 30/06/2025 Nanomedicina basada en RNA per al tractament del càncer. IP: Miguel Segura Ginard Colaboradores: Ariadna Boloix Amenós Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 100000 Referencia: 2021 PROD 00059 Duración: 19/10/2022 - 19/04/2024 Paginación Página actual 1 Página 2 Siguiente página › Última página »
